Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Lee, SH"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 52
Tytuł:
Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.
Autorzy:
Lee SM; Department of Biomedical Sciences, Graduate School of Medicine, Korea University, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.; Department of Applied Chemistry, Kookmin University, 77, Jeongneung-ro, Seongbuk-gu, Seoul, 02707, Republic of Korea.
Min SW; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea.
Kwon HS; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea.
Bae GD; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea.
Jung JH; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea.
Park HI; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea.
Lee SH; Department of Biomedical Sciences, Graduate School of Medicine, Korea University, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
Lim CS; New Drug Development Center, Osong Medical Innovation Foundation 123, Cheongju, Chungcheongbuk-do, 28160, Republic of Korea.
Ko BJ; School of Biopharmaceutical and Medical Science, Sungshin Women's University, 55, Dobonng-Ro 76ga-gil, Gangbuk, Seoul, 01133, Republic of Korea.
Lee JC; SG Medical, 3-11, Ogeum-ro 13-gil, Songpa-gu, Seoul, 05548, Republic of Korea. .
Jung ST; Department of Biomedical Sciences, Graduate School of Medicine, Korea University, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. .; BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. .; Institute of Human Genetics, Korea University College of Medicine, Seoul, 02841, Republic of Korea. .; Biomedical Research Center, Korea University Anam Hospital, Seoul, 02841, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 25; Vol. 13 (1), pp. 18275. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Antibodies, Bispecific*/pharmacology
Humans ; Rituximab/pharmacology ; Immunoglobulin G ; Antibodies, Monoclonal, Murine-Derived/pharmacology ; Antigens, CD20 ; CD55 Antigens/metabolism ; Cell Line, Tumor ; Antibody-Dependent Cell Cytotoxicity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
Autorzy:
Choi SW; Department of Neurosurgery, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
Jung HA; Department of Medicine, Division of Hematology-Oncology, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
Cho HJ; Department of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, Republic of Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Park CK; Department of Neurosurgery, Seoul National University Hospital, College of Medicine, Seoul, Republic of Korea.
Nam DH; Department of Neurosurgery, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
Lee SH; Department of Medicine, Division of Hematology-Oncology, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 15788-15796. Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:
Clinical Trial, Phase II; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Antineoplastic Agents*/therapeutic use
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Humans ; In Situ Hybridization, Fluorescence ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Chronic Disease
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.
Autorzy:
Lee JH; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim EY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Park CK; Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Lee SY; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Lee MK; Division of Pulmonology, Allergy and Critical care medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Yoon SH; Department of Pulmonology and Critical care medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
Lee JE; Division of Pulmonology, Department of Internal Medicine, Chungnam National University, Daejeon, Korea.
Lee SH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim SJ; Divi-sion of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Lee SY; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Lim JH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Jang TW; Department of Pulmonology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
Jang SH; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Lee KY; Department of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, Korea.
Lee SH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
Yang SH; Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea.
Park DW; Division of Pulmonology, Allergy and Critical care medicine, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
Park CK; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kang HS; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
Yeo CD; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Choi CM; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JC; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Jan; Vol. 55 (1), pp. 112-122. Date of Electronic Publication: 2022 Jul 19.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Antineoplastic Agents*/adverse effects
Humans ; ErbB Receptors/genetics ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Republic of Korea
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity.
Autorzy:
Shin MK; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Jang BY; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Bu KB; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Lee SH; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Han DH; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Oh JW; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Sung JS; Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Dec 09; Vol. 23 (24). Date of Electronic Publication: 2022 Dec 09.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
Peptides*/pharmacology
Humans ; A549 Cells ; Cell Line, Tumor ; Epithelial-Mesenchymal Transition
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems.
Autorzy:
Bajracharya R; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Song JG; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Patil BR; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Lee SH; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Noh HM; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Kim DH; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Kim GL; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Seo SH; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Park JW; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Jeong SH; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Lee CH; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Han HK; College of Pharmacy, Dongguk University-Seoul, Goyang, Korea.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 1959-1970.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*
Quality of Life*
Drug Delivery Systems ; Humans ; Ligands ; Pharmaceutical Preparations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation.
Autorzy:
Seo W; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.
Yoo S; Sema4, Stamford, CT, USA.
Zhong Y; Sema4, Stamford, CT, USA.
Lee SH; Center for Research Equipment, Korea Basic Science Institute, Cheongju, South Korea.
Woo SY; Department of Convergence Medicine, School of Medicine, Pusan National University, Yangsan, South Korea.
Choi HS; Department of Convergence Medicine, School of Medicine, Pusan National University, Yangsan, South Korea.
Won M; Biotechnology Process Engineering Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju, South Korea.
Roh T; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.
Jeon SM; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.
Kim KT; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.
Silwal P; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.
Lee MJ; Department of Biochemistry, Chungnam National University College of Medicine, Daejeon, South Korea.
Heo JY; Department of Biochemistry, Chungnam National University College of Medicine, Daejeon, South Korea.
Lawlor N; Sema4, Stamford, CT, USA.
Kim S; Department of Radiation Oncology, Chungnam National University Hospital, Daejeon, South Korea.
Lee D; Department of Convergence Medicine, School of Medicine, Pusan National University, Yangsan, South Korea.
Kim JM; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea.; Department of Pathology, Chungnam National University College of Medicine, Daejeon, South Korea.
Song IC; Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, South Korea. .
Zhu J; Sema4, Stamford, CT, USA. .; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .
Jo EK; Department of Medical Science and Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea. .; Infection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon, South Korea. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2022 Oct 26; Vol. 15 (1), pp. 156. Date of Electronic Publication: 2022 Oct 26.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/genetics
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Mice ; Animals ; Oxidative Phosphorylation ; Apoptosis ; Mitochondria/metabolism ; Cell Line, Tumor ; Cell Proliferation ; ERRalpha Estrogen-Related Receptor
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling.
Autorzy:
Zhang Y; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Qiu F; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Ye T; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Lee SH; School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Lakeside Campus, Subang Jaya, Selangor, Malaysia.
Xu J; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jia L; ZJU-UoE Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, China.
Zeng R; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Wang X; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Hu X; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yan X; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Li H; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Lu Y; Department of Oncology and Institute of Traditional Chinese Medicine in Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wang X; ZJU-UoE Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, China.
Jiang R; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. .
Xu W; School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. .
Pokaż więcej
Źródło:
Stem cell research & therapy [Stem Cell Res Ther] 2022 May 12; Vol. 13 (1), pp. 197. Date of Electronic Publication: 2022 May 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Epiregulin/genetics ; Epiregulin/metabolism ; Epiregulin/pharmacology ; Humans ; Intercellular Signaling Peptides and Proteins/pharmacology ; Signal Transduction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protective Effect of Agmatine Against Cisplatin- Induced Cellular Apoptosis in an Auditory Cell Line.
Autorzy:
Park E; Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.
Lee SH; Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.
Jung HH; Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.
Im GJ; Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
The journal of international advanced otology [J Int Adv Otol] 2022 May; Vol. 18 (3), pp. 257-263.
Typ publikacji:
Journal Article
MeSH Terms:
Agmatine*/pharmacology
Antineoplastic Agents*/pharmacology
Apoptosis ; Caspase 3/metabolism ; Caspase 3/pharmacology ; Cell Line ; Cell Survival ; Cisplatin/pharmacology ; Reactive Oxygen Species/metabolism ; bcl-2-Associated X Protein/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Anticancer Effects of Propionic Acid Inducing Cell Death in Cervical Cancer Cells.
Autorzy:
Pham CH; Biometrology Group, Korea Research Institute of Standards and Science, Daejeon 34113, Korea.; Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea.
Lee JE; Department of Physiology, Daegu Catholic University School of Medicine, Daegu 42472, Korea.
Yu J; Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul 02792, Korea.
Lee SH; College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.
Yu KR; Department of Agricultural Biotechnology, Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea.
Hong J; Department of Physiology, Daegu Catholic University School of Medicine, Daegu 42472, Korea.
Cho N; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Korea.
Kim S; Biometrology Group, Korea Research Institute of Standards and Science, Daejeon 34113, Korea.; Convergent Research Center for Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.; Department of Bio-Analytical Science, University of Science & Technology (UST), Daejeon 34113, Korea.
Kang D; Biometrology Group, Korea Research Institute of Standards and Science, Daejeon 34113, Korea.
Lee S; Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea.
Yoo HM; Biometrology Group, Korea Research Institute of Standards and Science, Daejeon 34113, Korea.; Department of Bio-Analytical Science, University of Science & Technology (UST), Daejeon 34113, Korea.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2021 Aug 16; Vol. 26 (16). Date of Electronic Publication: 2021 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Propionates/*pharmacology
Uterine Cervical Neoplasms/*pathology
Antineoplastic Agents/chemistry ; Autophagy/drug effects ; Cell Cycle/drug effects ; Cell Death/drug effects ; Female ; HeLa Cells ; Humans ; Mitochondrial Membranes/drug effects ; Mitochondrial Membranes/metabolism ; NF-kappa B/metabolism ; Propionates/chemistry ; Reactive Oxygen Species/metabolism ; Signal Transduction/drug effects ; Uterine Cervical Neoplasms/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
Autorzy:
Kim SC; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee WH; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kim SH; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Abdulkhayevich AA; Department of Urology, Akfa Medline, Tashkent, Uzbekistan.
Park JW; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kim YM; Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Moon KH; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee SH; Department of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Park S; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. .
Pokaż więcej
Źródło:
Investigative and clinical urology [Investig Clin Urol] 2021 Jul; Vol. 62 (4), pp. 485-495.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Docetaxel/*pharmacology
GTP-Binding Proteins/*genetics
GTP-Binding Proteins/*metabolism
Prostatic Neoplasms, Castration-Resistant/*genetics
Apoptosis/genetics ; Cell Proliferation/drug effects ; G1 Phase Cell Cycle Checkpoints/drug effects ; G1 Phase Cell Cycle Checkpoints/genetics ; G2 Phase Cell Cycle Checkpoints/drug effects ; G2 Phase Cell Cycle Checkpoints/genetics ; Gene Expression/drug effects ; Gene Knockdown Techniques ; Humans ; M Phase Cell Cycle Checkpoints/drug effects ; M Phase Cell Cycle Checkpoints/genetics ; Male ; PC-3 Cells ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; RNA, Small Interfering ; Transfection
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study).
Autorzy:
Lee SH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Park CK; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Lee SY; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 Apr; Vol. 12 (8), pp. 1264-1268. Date of Electronic Publication: 2021 Feb 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Afatinib/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Squamous Cell/*drug therapy
Immunotherapy/*methods
Afatinib/pharmacology ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Squamous Cell/pathology ; Female ; Humans ; Male ; Prospective Studies ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy.
Autorzy:
Yun CW; Stembio. Ltd., Entrepreneur 306, Asan-si 31538, Korea.
Jeon J; Stembio. Ltd., Entrepreneur 306, Asan-si 31538, Korea.
Go G; Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31151, Korea.
Lee JH; Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Korea.; Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Korea.; Department of Oral Anatomy, College of Dentistry, Dankook University, Cheonan 31116, Korea.; Cell & Matter Institute, Dankook University, Cheonan 31116, Korea.
Lee SH; Stembio. Ltd., Entrepreneur 306, Asan-si 31538, Korea.; Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31151, Korea.; Medical Science Research Institute, Soonchunhyang University Seoul Hospital, Seoul 04401, Korea.; Department of Anatomy, BK21FORU Project2, College of Medicine, Soonchunhyang University, Cheonan 31151, Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Dec 26; Vol. 22 (1). Date of Electronic Publication: 2020 Dec 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Autophagy*
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Neoplastic Stem Cells/*drug effects
Animals ; Humans ; Neoplasms/pathology ; Neoplastic Stem Cells/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer.
Autorzy:
Lee SH; Department of Pharmacy, National University of Singapore, Singapore City, Singapore.
Mahendran R; Department of Surgery, National University of Singapore, Singapore City, Singapore.
Tham SM; Department of Surgery, National University of Singapore, Singapore City, Singapore.; Department of Urology, National University Hospital, Singapore City, Singapore.
Thamboo TP; Department of Pathology, National University Hospital, Singapore City, Singapore.
Kioh DYQ; Department of Pharmacy, National University of Singapore, Singapore City, Singapore.
Tang LWT; Department of Pharmacy, National University of Singapore, Singapore City, Singapore.
Chiong E; Department of Surgery, National University of Singapore, Singapore City, Singapore.; Department of Urology, National University Hospital, Singapore City, Singapore.
Esuvaranathan K; Department of Surgery, National University of Singapore, Singapore City, Singapore.; Department of Urology, National University Hospital, Singapore City, Singapore.
Chan ECY; Department of Pharmacy, National University of Singapore, Singapore City, Singapore.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2020 Nov; Vol. 126 (5), pp. 554-556. Date of Electronic Publication: 2020 Aug 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Acetamides*/pharmacology
Acetamides*/therapeutic use
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
BCG Vaccine*/pharmacology
BCG Vaccine*/therapeutic use
Quinolines*/pharmacology
Quinolines*/therapeutic use
Urinary Bladder Neoplasms*/chemistry
Urinary Bladder Neoplasms*/drug therapy
Indoleamine-Pyrrole 2,3,-Dioxygenase/*antagonists & inhibitors
Animals ; Kynurenine/blood ; Mice ; Neoplasms, Experimental/chemistry ; Neoplasms, Experimental/drug therapy ; Urinary Bladder/chemistry ; Urinary Bladder/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling.
Autorzy:
Lee JS; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.
Lee H; Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Jang H; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Woo SM; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Park JB; Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Lee SH; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Kang JH; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Kim HY; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Song J; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.
Kim SY; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Korea.
Pokaż więcej
Źródło:
Cells [Cells] 2020 Sep 01; Vol. 9 (9). Date of Electronic Publication: 2020 Sep 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Autophagy/*drug effects
Drug Resistance, Neoplasm/*drug effects
Gossypol/*therapeutic use
Neoplasms/*drug therapy
Neoplasms/*metabolism
Oxidative Phosphorylation/*drug effects
Phenformin/*therapeutic use
Aldehyde Dehydrogenase/antagonists & inhibitors ; Animals ; Antineoplastic Agents/pharmacology ; Drug Synergism ; Electron Transport Complex I/antagonists & inhibitors ; Gossypol/pharmacology ; HT29 Cells ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Mitochondria/drug effects ; Mitochondria/metabolism ; Neoplasms/pathology ; Phenformin/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Expression and In Vitro Function of Anti-Breast Cancer Llama-Based Single Domain Antibody VHH Expressed in Tobacco Plants.
Autorzy:
Park SR; Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea.
Lee JH; Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea.
Kim K; Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea.; Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul 156-756, Korea.
Kim TM; Major of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon-National University, Incheon 22012, Korea.
Lee SH; Major of Nano-Bioengineering, College of Life Sciences and Bioengineering, Incheon-National University, Incheon 22012, Korea.
Choo YK; Department of Biological science, College of Natural Sciences, Wonkwang University, 460, Iksan-daero, Iksan-si, Jeollabuk-do 54538, Korea.
Kim KS; Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul 156-756, Korea.
Ko K; Department of Medicine, Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Feb 17; Vol. 21 (4). Date of Electronic Publication: 2020 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*immunology
Breast Neoplasms/*immunology
Immunoglobulin Heavy Chains/*genetics
Immunoglobulin Heavy Chains/*immunology
Receptor, ErbB-2/*immunology
Nicotiana/*genetics
Nicotiana/*metabolism
Animals ; Antineoplastic Agents/pharmacology ; Breast ; Camelids, New World ; Cell Line, Tumor ; Cell Movement ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunoglobulin G/immunology ; Neoplasm Recurrence, Local ; Plantibodies ; Plants, Genetically Modified/genetics ; Trastuzumab
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Autorzy:
Lee JW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kim NKD; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Geninus Inc., Seoul, Korea.
Lee SH; Department of Translational Molecular Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States of America.
Cho HW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ma Y; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ju HY; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Yoo KH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sung KW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Koo HH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park WY; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Geninus Inc., Seoul, Korea.; Department of Health Science and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Nov 20; Vol. 14 (11), pp. e0224227. Date of Electronic Publication: 2019 Nov 20 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*genetics
Drug Resistance, Neoplasm/*genetics
Neoplasm Recurrence, Local/*genetics
Neoplasms/*genetics
Adolescent ; Aminopyridines ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Anaplastic Lymphoma Kinase/genetics ; Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/antagonists & inhibitors ; Child ; Child, Preschool ; DNA Copy Number Variations ; DNA Mutational Analysis ; Exons/genetics ; Feasibility Studies ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Infant ; Lactams ; Lactams, Macrocyclic/pharmacology ; Lactams, Macrocyclic/therapeutic use ; Male ; Molecular Targeted Therapy/methods ; Mutation ; Neoplasm Recurrence, Local/prevention & control ; Neoplasms/drug therapy ; Precision Medicine/methods ; Pyrazoles ; Republic of Korea ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.
Autorzy:
Park S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Ha S; Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University Hospital, Seoul, Republic of Korea.
Lee SH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Paeng JC; Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University Hospital, Seoul, Republic of Korea.
Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Heo DS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Jan 31; Vol. 13 (1), pp. e0189766. Date of Electronic Publication: 2018 Jan 31 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*pathology
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*pathology
Positron-Emission Tomography/*methods
Protein Kinase Inhibitors/*therapeutic use
Carcinoma, Non-Small-Cell Lung/diagnostic imaging ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Disease-Free Survival ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Mutation ; Tomography, X-Ray Computed
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synthesis and In Vitro Antiproliferative Activity of New 1-Phenyl-3-(4-(pyridin-3-yl)phenyl)urea Scaffold-Based Compounds.
Autorzy:
Al-Sanea MM; Department of Pharmaceutical Chemistry, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .
Ali Khan MS; Department of Pharmacology, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .; Department of Pharmacology, Anwarul Uloom College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad 500001, Telangana, India. .; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. .
Abdelazem AZ; Department of Biotechnology & Life Sciences, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62574, Egypt. .
Lee SH; Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea. .
Mok PL; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. pooi_.; Genetics and Regenerative Medicine Research Centre, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. pooi_.
Gamal M; Department of Pharmaceutical Chemistry, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmed Hegazy St., Beni-Suef 62574, Egypt. .
Shaker ME; Department of Pharmacology, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. .
Afzal M; Department of Pharmacology, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .
Youssif BGM; Department of Pharmaceutical Chemistry, College of Pharmacy, Aljouf University, Sakaka 2014, Aljouf Province, Saudi Arabia. .; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. .
Omar NN; Department of Biochemistry, Faculty of Pharmacy, Modern University for Technology & Information, 11571 Cairo, Egypt. .
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2018 Jan 31; Vol. 23 (2). Date of Electronic Publication: 2018 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemical synthesis
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Phenylurea Compounds*/chemical synthesis
Phenylurea Compounds*/chemistry
Phenylurea Compounds*/pharmacology
Cell Proliferation/*drug effects
Neoplasms/*drug therapy
Cell Line, Tumor ; Humans ; Neoplasms/metabolism ; Neoplasms/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Autorzy:
Lee HW; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim HS; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim SU; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Kim DY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Kim BK; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Park JY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Ahn SH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Jeon MY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Heo JY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Park SY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Lee YR; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Jang SK; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Lee SH; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Jang SY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Tak WY; Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Han KH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.; Liver Cirrhosis Clinical Research Center, Seoul, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2017 Sep 15; Vol. 11 (5), pp. 693-701.
Typ publikacji:
Journal Article; Validation Study
MeSH Terms:
Antineoplastic Agents*
Phenylurea Compounds*
Severity of Illness Index*
Carcinoma, Hepatocellular/*mortality
Liver Neoplasms/*mortality
Niacinamide/*analogs & derivatives
Withholding Treatment/*statistics & numerical data
Aged ; Area Under Curve ; Carcinoma, Hepatocellular/drug therapy ; Female ; Humans ; Liver Neoplasms/drug therapy ; Male ; Middle Aged ; ROC Curve ; Retrospective Studies ; Risk Factors ; Sorafenib ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Autorzy:
Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim TY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Im YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee KS; Division of Hematology and Medical Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Korea.
Park IH; Division of Hematology and Medical Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Korea.
Sohn J; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lee SH; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Im SA; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Kim JH; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim SH; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Lee SJ; Division of Hematology and Medical Oncology, Department of Internal Medicine, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea.
Koh SJ; Division of Medical Oncology, Department of Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee KH; Division of Hematology-Oncology, Department of Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
Choi YJ; Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Cho EK; Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Lee S; Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea.
Kang SY; Division of Hematology and Medical Oncology, Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.
Seo JH; Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2017 Apr; Vol. 49 (2), pp. 423-429. Date of Electronic Publication: 2016 Aug 03.
Typ publikacji:
Clinical Trial, Phase IV; Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*pathology
Furans/*therapeutic use
Ketones/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biomarkers, Tumor ; Breast Neoplasms/mortality ; Combined Modality Therapy ; Female ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Republic of Korea ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 52

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies